<DOC>
	<DOCNO>NCT01601457</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate efficacy activate recombinant human factor VIIgiven conjunction standard therapy patient undergo major orthopaedic surgery follow traumatic pelvic pelvic acetabular fracture .</brief_summary>
	<brief_title>Activated Recombinant Human Factor VII Pelvic-acetabular Fracture Reconstruction</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Injury due blunt penetrate trauma cause pelvic pelvic acetabular fracture amenable surgical reconstruction Scheduled semielective reconstruction surgery fracture ( ) pelvis pelvis acetabulum , expect `` large '' complex procedure potential blood loss 50 % circulate blood volume A history thrombosis ( deep vein thrombosis , pulmonary embolism , cerebral thrombosis ) Patients severe head injury abnormal compute tomography ( CT ) scan head due head injury Body weight exceed 135 kg Cardiac arrest follow trauma prior surgery Known congenital bleeding disorder Known pregnancy positive pregnancy test enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>